An episode-based payment model cut the cost of breast cancer treatment by 34%, ac­cording to Lee N. Newcomer, MD, MHA
Implementing a clinical pathway for stage IV non–small-cell lung cancer (NSCLC) led to a reduction in chemotherapy drug costs at the Cleveland Clinic, reported James P. Stevenson, MD.
The prevention of common skin cancers and precancers is possible by taking an inexpensive, widely available, oral pill twice daily.
Although still a relatively new technique, research is moving fast. Data from 3 separate clinical trials presented at ASCO 2015 highlight the progress being made.
Pembrolizumab achieved “remarkable” results in a phase 1 study of previously treated patients with recurrent, squamous-cell carcinoma of the head and neck, according to presenters at ASCO 2015.
Pembrolizumab achieved “remarkable” results in a phase 1 study of previously treated patients with recurrent, squamous-cell carcinoma of the head and neck, according to presenters at ASCO 2015.
Lenvatinib added to everolimus extended overall survival (OS) significantly compared with everolimus alone in patients with metastatic renal-cell carcinoma (RCC).
Immunotherapy with nivolumab resulted in durable responses and promising overall survival (OS) in a dose-escalation and expansion trial of patients with advanced liver cancer.
A clinical trial has shown that patients with a specific molecular subtype of diffuse large B-cell lymphoma (DLBCL) are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease.
Page 2 of 4
Results 11 - 20 of 37
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME